Latest news with #SurgicalOncologyandRoboticServices
Time of India
4 days ago
- General
- Time of India
HCG Manavata Cancer Centre performs first PIPAC procedure for advanced abdominal cancer
Mumbai: HCG Manavata Cancer Centre (HCGMCC) has successfully performed its first PIPAC (Pressurised IntraPeritoneal Aerosol Chemotherapy ) procedure—an advanced, minimally invasive surgical technique used in the management of advanced abdominal cancers. The pioneering procedure was performed on a patient diagnosed with advanced-stage stomach cancer . The surgery was conducted under the expert guidance of Dr. Ninad Katdare from HCG Cancer Centre, Mumbai, in collaboration with Dr. Raj Nagarkar, Managing Director and Chief of Surgical Oncology and Robotic Services at HCGMCC. PIPAC is widely adopted in international oncology centers for treating peritoneal cancers deemed inoperable by conventional standards. This includes cancers originating in the stomach, ovaries, and colon. 'The breakthrough technique allows chemotherapy to be delivered directly into the peritoneal cavity in aerosolized form using laparoscopic access. The pressurized delivery improves drug penetration, allowing for targeted treatment with minimal systemic side effects. It not only maximizes the therapeutic effect of chemotherapy but also enhances patient comfort and recovery,' said Prof. Dr. Raj Nagarkar, Chief of Surgical Oncology and Robotic Services and Managing Director, KIMS Manavata Hospitals, HCG Manavata Cancer Centre and Six Sigma, Nashik. The key advantages of PIPAC include localised, high-concentration drug delivery directly into the peritoneal cavity, which enhances the therapeutic impact on cancerous tissues. It minimises toxicity to healthy organs, thereby reducing systemic side effects commonly associated with traditional chemotherapy. Patients also benefit from faster postoperative recovery due to the minimally invasive nature of the procedure.
Indian Express
06-05-2025
- Health
- Indian Express
Blood test detects 30 different types of cancers with 98.4% accuracy: Study
A multi-centre research team in the country has developed a blood test that can detect 30 different types of cancers including pancreatic, lung and ovarian cancers with an average accuracy of 98.4 per cent. Results of the phase 1 trial were recently published in Cancer Reports. Prof Dr Raj Nagarkar, Managing Director and Chief of Surgical Oncology and Robotic Services at HCG Manavata Cancer Centre, Nashik, told The Indian Express that the diagnostic test has shown a consistent sensitivity during the phase 1 clinical trial. 'We utilised a novel serum metabolome-based diagnostic platform powered by machine learning to identify distinct metabolic signatures associated with cancer,' Dr Nagarkar said. Around six hospitals from Kolkata, Bengaluru, Vijaywada, Singapore, Kolkata and Guwahati were involved in the trial that commenced in 2021. What this test does is to capture changes in the metabolites to provide a reliable and sensitive readout, especially for early-stage cancers. Metabolomics is the study of tiny molecules 'metabolites' in the body like sugars, fats and amino acids. It can help identify early signs of diseases including cancer, diabetes and so on. 'The serum samples were analysed using high-resolution mass spectrometry and the data was interpreted through a proprietary Cancer Detection Artificial Intelligence (CDAI) algorithm developed in collaboration with PredOmix Technologies,' Dr Nagarkar said. As per the study, the test profiles over 8,000 metabolites in blood serum. 'In a clinical trial involving 6,445 participants, including 2,831 cancer patients, the test demonstrated near-perfect accuracy across all stages (I–IV) and age groups (20 to 80+ years). It identified Stage I cancers with 98.9 per cent sensitivity,' Dr Nagarkar said. 'In the second phase of the trial we are planning to include 5000 women participants,' Dr Nagarkar added.
